Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ASCENDIS PHARMA A/S

(ASND)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ascendis Pharma A/S Reports Earnings Results for the Second Quarter Ended June 30, 2021

08/25/2021 | 04:12pm EST

Ascendis Pharma A/S announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was EUR 1.022 million compared to EUR 1.436 million a year ago. Operating loss was EUR 117.629 million compared to EUR 82.947 million a year ago. Net loss was EUR 134.374 million compared to EUR 94.932 million a year ago. Basic loss per share from continuing operations was EUR 2.5 compared to EUR 1.97 a year ago. For the half year, sales was EUR 1.767 million compared to EUR 3.661 million a year ago. Operating loss was EUR 242.279 million compared to EUR 156.152 million a year ago. Net loss was EUR 197.166 million compared to EUR 158.249 million a year ago. Basic loss per share from continuing operations was EUR 3.66 compared to EUR 3.29 a year ago.


ę S&P Capital IQ 2021
All news about ASCENDIS PHARMA A/S
11/18Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forwar..
GL
11/18Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward..
CI
11/18Ascendis Pharma A/S Elects Rafa?le Tordjman as A Class II Director
CI
11/17Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference
AQ
11/16European ADRs Mixed in Tuesday Morning Trading
MT
11/15SVB Leerink Adjusts Ascendis Pharma's Price Target to $190 from $182, Keeps Outperform ..
MT
11/15Ascendis Pharma A/S - Share Repurchase Program Update
AQ
11/12Ascendis Pharma Says EMA Panel Issues Positive Opinion Backing Approval of Growth Hormo..
MT
11/12Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients..
GL
11/12Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon? hGH for Patients with ..
CI
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2021 7,69 M 8,71 M 8,71 M
Net income 2021 -401 M -454 M -454 M
Net cash 2021 677 M 766 M 766 M
P/E ratio 2021 -17,0x
Yield 2021 -
Capitalization 6 866 M 7 772 M 7 770 M
EV / Sales 2021 804x
EV / Sales 2022 90,4x
Nbr of Employees 482
Free-Float 10,5%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 125,12 €
Average target price 171,04 €
Spread / Average Target 36,7%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-15.09%7 772
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.30.33%66 734
REGENERON PHARMACEUTICALS31.76%66 553
VERTEX PHARMACEUTICALS-20.90%47 530